Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: art slott who wrote (2685)	9/2/1998 7:28:00 AM
From: Bruce Rozenblit	Read Replies (1) \| Respond to of 3725

Art, You left out the most important quote: "Although the scan is as accurate as angiography - a highly accurate imaging study commonly used to measure the extent of heart disease - it is less expensive and less risky, according to lead author, Dr. Alan Guerci, of St. Francis Hospital in Roslyn, New York." If the scanner can be demonstrated to be equal to angiography at only 10 to 15% of the cost with no risk or discomfort to the patient, and in only 10 minutes time, that is super attractive to the insurance companies. Patients want comfortable procedures so doctors like to say "come to my clinic for "no pain" care" There is no question about the usefulness of angiogaphy. The demand is huge. What will it take now to sell the blasted thing?